NCI Reveals Alliance for Nanotechnology in Cancer's $150 Million in Grants
The National Cancer Institute has announced some $150 million in research funding over 5 years to institutions targeting nanotechnology approaches to detect, fight and treat cancer. More than 30 institutions across the country will receive nanocancer funding.
The NCL will continue to serve as a hub for the pre-clinical characterization of nanomaterials and to assist in the process of bringing nanotechnologies to the stage of investigational new drug or device submissions to U.S. Food and Drug Administration (FDA).
NCI also announced two new programs to support what the institute called “critically needed training [to develop] the next-generation of cancer researchers in the area of nanotechnology.” These training programs are: Pathway to Independence Awards in Cancer Nanotechnology Research and the Cancer Nanotechnology Training Centers.
NCI’s Cancer Nanotechnology Platform Partnerships engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These “platforms” will serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.
CNPPs are designed to enable multi-disciplinary team research and transformative discoveries in basic and pre-clinical cancer research and help overcome barriers help answer fundamental questions in cancer biology, diagnosis, prevention and treatment of the disease using innovative nanotechnology solutions.
The updated list of CNPP awarded programs (and their institutions and investigators) include:
Combinatorial-designed Nano-platforms to Overcome Tumor Resistance
Principal Investigators: Mansoor Amiji, R.Ph., Ph.D., and Zhen-feng Duan, Ph.D.
High Capacity Nanocarriers for Cancer Therapeutics
University of Nebraska Medical Center
Principal Investigator: Alexander Kabanov, Ph.D, D.Sc.
Magnetoresistive Sensor Platform for Parallel Cancer Marker Detection
University of Utah
Principal Investigators: Marc Porter, Ph.D., and Sean J. Mulvihill, M.D.
Nanoconjugate Based on Polymalic Acid for Brain Tumor Treatment
Cedars-Sinai Medical Center
Principal Investigator: Julia Ljubimova, M.D., Ph.D.
Nanoscale Metal-Organic Frameworks for Imaging and Therapy of Pancreatic Cancer
University of North Carolina
Principal Investigators: Wenbin Lin, Ph.D., and Jen Jen Yeh, M.D.
Peptide Directed Protocells and Virus-like Particles – New Nanoparticle Platforms for Targeted Cellular Delivery of Multicomponent Cargo
University of New Mexico
Principal Investigators: Cheryl Willman, M.D., and C. Jeffrey Brinker, Ph.D.
Preclinical Platform for Theranostic Nanoparticles in Pancreatic Cancer
Principal Investigators: Naomi Halas, Ph.D., D.Sc., and Peter Nordlander, Ph.D.
RNA Nanotechnology in Cancer Therapy
University of Cincinnati
Principal Investigators: Peixuan Guo, D.V.M., Ph.D., John Rossi, Ph.D., and Joseph Trebley, Ph.D.
Targeting SKY Kinase in B-Lineage ALL with CD-19 Specific C-61 Nanoparticles
Children’s Hospital Los Angeles
Principal Investigator: Fatih Uckun, M.D., Ph.D.
Theranostic Nanoparticles for Targeting Treatment of Pancreatic Cancer
Principal Investigators: Lily Yang, M.D., Ph.D., and Hui Mao, Ph.D.
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer
Principal Investigators: Dong Shin, M.D., and Mostafa El-Sayed, Ph.D.
Tumor Targeted Nanobins for the Treatment of Metastatic Breast and Ovarian Cancer
Principal Investigators: Thomas O’Halloran, Ph.D., and Vincent Cryns, M.D.
Centers of Cancer Nanotechnology Excellence awarded institutions (and investigators) include:
California Institute of Technology, Pasadena, Calif. Principal Investigators: James Heath, Ph.D., Leroy Hood, M.D., Ph.D., and Michael Phelps, Ph.D.
Dartmouth College, Hanover, N.H. Principal Investigator: Ian Baker, Ph.D.
Johns Hopkins University, Baltimore, Md. Principal Investigators: Peter Searson, Ph.D., and Martin Pomper, M.D., Ph.D.
Massachusetts Institute of Technology and Harvard University, Cambridge, Mass. Principal Investigators: Robert Langer, Sc.D., and Ralph Weissleder, M.D., Ph.D.
Northeastern University, Boston, Mass. Principal Investigators: Vladimir Torchilin, Ph.D., D.Sc., and Nahum Goldberg, M.D.
Northwestern University, Evanston, Ill. Principal Investigators: Chad Mirkin, Ph.D., and Steven Rosen, M.D.
Stanford University, Palo Alto, Calif. Principal Investigators: Sanjiv Sam Gambhir, M.D., Ph.D., and Shan Wang, Ph.D.
The University of Texas Health Science Center, Houston, Texas. Principal Investigators: Mauro Ferrari, Ph.D., Anil Sood, M.D., and G. Lopez-Berestein, M.D.
University of North Carolina, Chapel Hill, N.C. Principal Investigators: Joseph DeSimone, Ph.D. and Joel Tepper, M.D.
Cancer Nanotechnology Training Centers awards went to:
* Boston University, Boston, Mass.
Principal Investigator: Bennett Goldberg, Ph.D.
* Johns Hopkins University, Baltimore, Md.
Principal Investigator: Denis Wirtz, Ph.D.
* University of California San Diego, San Diego, Calif.
Principal Investigator: Robert Mattrey, M.D.
* University of Illinois Urbana-Champaign, Champaign, Ill.
Principal Investigator: Rashid Bashir, Ph.D.
* University of Kentucky, Lexington, Ky.
Principal Investigator: Bradley Anderson, Ph.D.
* University of New Mexico Health Sciences Center, Albuquerque, N.M.
Principal Investigator: Janet Oliver, Ph.D.
Pathway to Independence Awards in Cancer Nanotechnology Research went to
* Duke University, Durham, N.C.
Principal Investigator: Mingnan Chen, Ph.D.
* Emory University, Atlanta, Ga.
Principal Investigators: Aaron Mohs, Ph.D.
* Massachusetts General Hospital, Boston, Mass.
Principal Investigator: Prakash Rai, Ph.D.
* National Institute of Biomedical Imaging and Bioengineering, Bethesda, Md.
Principal Investigator: Jin Xie, Ph.D.
* Stanford University, Palo Alto, Calif.
Principal Investigator: Andrew M. Smith, Ph.D.
* University of California San Diego, San Diego, Calif.
Principal Investigator: Andrew Goodwin, Ph.D.
* Wake Forest University Health Sciences, Winston-Salem, N.C.
Principal Investigator: Ravi Singh, Ph.D.